Loading clinical trials...

Collection and Storage of Tissue and Blood Samples From Patients With Cancer | Clinical Trials | Clareo Health

RECRUITING

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

NCT02474160•National Cancer Institute LAO

Summary

This study collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scientists create new and better models to learn about cancer and to test new cancer drugs.

Detailed Description

PRIMARY OBJECTIVE: I. To procure biologic tissues and materials to generate preclinical models of cancer. OUTLINE: This is an observational study. Tumor tissue and blood samples are procured during procedures that are required for the patients' clinical management and will be stored via xenograft (transplant to another species) models or in vitro cell culture for future analysis.

Eligibility

Age

0 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients older than 2 months of age who are being evaluated, treated, or enrolled in a clinical trial for cancer at participating sites
•Patients with a histologically or cytologically confirmed diagnosis of cancer
•Patients without histologically or cytologically confirmed diagnosis of cancer, but for whom approval has been requested and received from the coordinating site study coordinator
•* Requests for coordinating site approval should only be made if the patient's existing work-up at the time of the request demonstrates a combination of two or more of the following indicating the greater likelihood of a cancerous process in the assessment of the treating physician:
•* Radiographic imaging (computed tomography \[CT\], magnetic resonance imaging \[MRI\], etc.)
•* Elevated tumor markers
•* Clinical symptoms
•* Documented risk factors, known genetic changes (mutation, deletion, fusion, etc.), and/or known familial cancer history or syndrome
•* Complete blood count (CBC) w/differential indicative of a probable hematologic malignancy
•* If the patient will be undergoing surgical resection at a later time and will be accessible to approach for study participation at that time, resected material following cancer diagnosis confirmation is preferred
+14 more criteria

Exclusion Criteria

•Patients with cancer-like syndromes and/or blood disorders such as systemic mastocytosis, Langerhans cell histiocytosis, chronic eosinophilic leukemia/hypereosinophilic syndrome, lymphomatoid granulomatosis, or monoclonal gammopathy of undetermined significance (MGUS)
•Patients with invasive fungal infections
•Patients with active and/or uncontrolled bacterial, fungal, or viral infections or who are still recovering from an infection
•* Actively febrile patients with uncertain etiology of febrile episode
•* All antibiotics prescribed for the treatment of a bacterial infection should be completed at least 1 week (7 days) prior to collection
•* Patients with a hematologic malignancy who are treated with an antibiotic, anti-fungal, and/or anti-viral medication for an active infection who then remain on the treatment for prophylaxis following resolution of the infection as assessed by the treating physician are not excluded
•* No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
•* Patients receiving antibiotics, antifungals, and/or antivirals for prophylaxis are permissible
•* Antibiotics being administered topically at a location distant from the planned tissue collection site or eye drops for a localized infection are permissible
•Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e., quantifiable hepatitis B virus \[HBV\]-deoxyribonucleic acid \[DNA\] and/or positive hepatitis B surface antigen \[HbsAg\], quantifiable hepatitis C virus \[HCV\]-ribonucleic acid \[RNA\]) or known history of HCV, HBV, or HIV; testing for HBV, HCV, HIV or other infections for eligibility will be performed only if clinically indicated
+3 more criteria

Locations (140)

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, United States

Mercy Hospital Fort Smith

Fort Smith, Arkansas, United States

PCR Oncology

Arroyo Grande, California, United States

City of Hope Comprehensive Cancer Center

Duarte, California, United States

USC / Norris Comprehensive Cancer Center

Los Angeles, California, United States

UCHealth University of Colorado Hospital

Aurora, Colorado, United States

Smilow Cancer Center/Yale-New Haven Hospital

New Haven, Connecticut, United States

Yale University

New Haven, Connecticut, United States

Delaware Clinical and Laboratory Physicians PA

Newark, Delaware, United States

Helen F Graham Cancer Center

Newark, Delaware, United States

Key Dates

Start Date

May 19, 2015

Primary Completion Date

May 4, 2026

Completion Date

May 4, 2026

Last Updated

March 5, 2026

Enrollment

5,000

ESTIMATED participants

Conditions

Hematopoietic and Lymphatic System NeoplasmMalignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid Neoplasm

Interventions

Cytology Specimen Collection Procedure

OTHER

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

NCT06126276

Malignant Female Reproductive System NeoplasmMalignant Solid Neoplasm+2 more

View study

RECRUITINGPHASE2

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

NCT06311214

Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 5, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

Inclusion Criteria

Exclusion Criteria

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial